Newsbenzinga
This $3 Biotech Could Be Worth $11.45, Analyst Says
· Published
Article summary
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
An excerpt from the original article.
Comments —
Loading comments…